Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This clinical trial is for men and women who have Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia.
The purpose of this research is to gather information on the safety and effectiveness of PBCAR0191. PBCAR0191 is a new investigational treatment for certain types of blood cancers, such as leukemia and lymphoma, and is made from a type of blood cells known as T cells.
Investigational means that PBCAR0191 has not yet been approved by the United States Food and Drug Administration (FDA).
The T cells in PBCAR0191 come from people who have donated their blood. The donated T cells have been genetically changed so that they may be able to kill some types of cancer cells.
All participants will receive PBCAR0191 through an IV infusion at a dose determined by the study team. Participation in this research will last about 24 months.
-Men and women with a confirmed diagnosis of Non-Hodgkin Lymphoma or B-Cell Acute Lymphoblastic Leukemia
Detailed eligibility will be reviewed when participants contact the study team.